Stanford Cancer Institute News
Stanford Cancer Institute News is a quarterly update for members, supporters and friends. On behalf of our members and staff, we thank you for your ongoing support and welcome your feedback and inquiries.
Featured Articles from the Current Issue
Artandi Succeeds Outgoing Director Beverly Mitchell, MD
Steven Artandi, MD, PhD, Named New Director of the Stanford Cancer Institute
Steven Artandi, MD, PhD, professor of medicine and of biochemistry at the School of Medicine, has been named the new Laurie Kraus Lacob Director of the Stanford Cancer Institute, effective October 1, 2018.
Pancreas Cancer Research Group Unites Scientists
Improving Outcomes in Pancreas Cancer
Research in pancreas cancer is essential to improving outcomes. In spring 2018, a group of Stanford Cancer Institute researchers and clinicians established the Pancreas Cancer Research Group (PCRG), a network of scientists interested in advancing research and care in pancreas cancer. The goal of the PCRG is to facilitate and expedite impactful research on pancreas cancer at Stanford.
How Do You See the Inner Working of a Cancer Cell?
Stanford’s Cell Sciences Imaging Facility
Inside a tumor, molecules zip from place to place, and cluster in unusual areas, helping cancer cells multiply at a speedy pace. To stop tumors from growing, scientists often must aim to put the brakes on these molecules. Doing so requires visualizing the molecules and cells in the first place. Luckily for cancer researchers, modern microscopy has lots to offer them.
Some Tumors May Be Born to Be Bad
Pioneering New Models of Tumor Progression
Tumor progression is assumed to be driven by ongoing mutation accumulation and selection, but researchers at the Stanford Cancer Institute have found that some tumors may be destined to invade or metastasize from the outset — they are “born to be bad.”
SCI member Christina Curtis, PhD, MSc, assistant professor of medicine (oncology) and of genetics, is pioneering the way for her “big bang” model, which proposes that mutations that occur during the earliest steps of tumor formation may determine how a tumor will progress.